ReviewiScience2025
Recent advances in bladder cancer stem cells (BCSCs): A descriptive review of emerging therapeutic targets.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants.Biomolecules · 2026Review
- Immunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing IL-13Rα2-In Vitro Study.International journal of molecular sciences · 2026Article
- Review
- Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.Journal of translational medicine · 2025Review
- Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BC) is the most common malignancy of the urinary system, characterized by high recurrence due to limited specificity and efficacy of current therapies. Bladder cancer stem cells (BCSCs), a distinct subpopulation within BC, exhibit self-renewal, tumorigenicity, and resistance to conventional treatments, playing a critical role in BC initiation, progression, metastasis, and recurrence. This study reviews the origins, biomarkers, and therapeutic potential of BCSCs, emphasizing emerging strategies targeting these cells. BCSCs can arise from urothelial stem cells or differentiated cells, with markers such as CD44, EZH2, ALDH1A1, and SOX2 enabling their identification. Aberrant activation of multiple signaling pathways, including Hedgehog, Notch, Wnt, PI3K/Akt, STAT3, and Hippo-YAP, drives BCSC function and therapy resistance. Targeting these pathways and markers offers promising therapeutic approaches to enhance efficacy and reduce recurrence. Understanding BCSC biology provides insights into improving treatment outcomes and advancing BC management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.